ASTE1

Summary

ASTE1 (asteroid structure-specific endonuclease 1, HGNC:25021) is a protein-coding gene on chromosome 3q22.1, encoding Single-strand DNA endonuclease ASTE1 (Q2TB18). Structure-specific DNA endonuclease that specifically cleaves single-stranded DNA and 3’ overhang DNA.

Enables 3’ overhang single-stranded DNA endodeoxyribonuclease activity. Involved in double-strand break repair via homologous recombination and double-strand break repair via nonhomologous end joining. Implicated in Lynch syndrome and mismatch repair cancer syndrome.

Source: NCBI Gene 28990 — RefSeq curated summary.

At a glance

• Gene–disease (curated): palmar fibromatosis (Limited, GenCC)
• GWAS associations: 2
• Clinical variants (ClinVar): 111 total
• MANE Select transcript: NM_014065

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:25021
Approved symbol	ASTE1
Name	asteroid structure-specific endonuclease 1
Location	3q22.1
Locus type	gene with protein product
Status	Approved
Aliases	HT001
Ensembl gene	ENSG00000034533
Ensembl biotype	protein_coding
OMIM	620693
Entrez	28990

Gene structure

Transcript identifiers

Ensembl transcripts: 18 — 16 protein_coding, 2 nonsense_mediated_decay

ENST00000264992, ENST00000504725, ENST00000504964, ENST00000505290, ENST00000505545, ENST00000507978, ENST00000509060, ENST00000514044, ENST00000874886, ENST00000874887, ENST00000874888, ENST00000874889, ENST00000928636, ENST00000928637, ENST00000928638, ENST00000928639, ENST00000972329, ENST00000972330

RefSeq mRNA: 2 — MANE Select: NM_014065 NM_001288950, NM_014065

CCDS: CCDS3068, CCDS75007

Canonical transcript exons

ENST00000264992 — 6 exons

Exon	Start	End
ENSE00000328922	131018506	131018716
ENSE00001018068	131013875	131014387
ENSE00001164451	131024005	131025331
ENSE00001283678	131025474	131025594
ENSE00001283683	131026507	131026825
ENSE00003560577	131016144	131016339

Expression profiles

Bgee: expression breadth ubiquitous, 233 present calls, max score 88.93.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 6.7543 / max 77.0003, expressed in 1703 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
44585	6.5564	1700
44584	0.1954	78
44586	0.0026	1

Top tissues by expression

278 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
sperm	CL:0000019	88.93	gold quality
male germ cell	CL:0000015	87.12	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	82.33	gold quality
granulocyte	CL:0000094	81.49	gold quality
calcaneal tendon	UBERON:0003701	80.41	gold quality
cortical plate	UBERON:0005343	79.23	gold quality
rectum	UBERON:0001052	79.00	gold quality
mucosa of transverse colon	UBERON:0004991	78.83	gold quality
blood	UBERON:0000178	78.26	gold quality
jejunal mucosa	UBERON:0000399	77.89	gold quality
ventricular zone	UBERON:0003053	77.88	gold quality
bone marrow cell	CL:0002092	77.36	gold quality
tendon	UBERON:0000043	77.33	gold quality
small intestine Peyer’s patch	UBERON:0003454	77.26	gold quality
amniotic fluid	UBERON:0000173	77.20	gold quality
colonic mucosa	UBERON:0000317	77.20	gold quality
lymph node	UBERON:0000029	77.10	gold quality
leukocyte	CL:0000738	76.86	gold quality
transverse colon	UBERON:0001157	76.86	gold quality
bone marrow	UBERON:0002371	76.80	gold quality
ganglionic eminence	UBERON:0004023	76.75	gold quality
small intestine	UBERON:0002108	76.47	gold quality
monocyte	CL:0000576	76.37	gold quality
mononuclear cell	CL:0000842	76.25	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	76.06	gold quality
secondary oocyte	CL:0000655	76.05	gold quality
duodenum	UBERON:0002114	75.95	gold quality
intestine	UBERON:0000160	75.92	gold quality
right lobe of liver	UBERON:0001114	75.86	gold quality
large intestine	UBERON:0000059	75.59	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	3.76

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

14 targeting ASTE1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-590-3P	99.96	74.34	6478
HSA-MIR-3942-3P	99.57	69.03	2854
HSA-MIR-5009-3P	99.45	69.43	1341
HSA-MIR-302A-5P	99.39	68.21	1913
HSA-MIR-5100	99.11	67.52	1098
HSA-MIR-5701	98.97	69.54	1502
HSA-MIR-455-3P	98.94	67.68	878
HSA-MIR-541-5P	98.24	67.77	1181
HSA-MIR-4483	98.09	64.12	1642
HSA-MIR-3159	97.94	66.79	1098
HSA-MIR-890	97.47	68.67	982
HSA-MIR-1910-5P	97.42	66.36	844
HSA-MIR-1293	96.16	64.69	916
HSA-MIR-191-5P	95.88	67.82	171

Literature-anchored findings (GeneRIF, showing 4)

• The four most frequently mutated genes in colorectal cancers with microsatellite instability were ACVR2 (92%), TAF1B (84%), ASTE1/HT001 (80%) and TGFBR2 (77%). (PMID:19503063)
• Data suggest that calcium ATPase ATP2C1 gene expression is influenced by an overlapping protein asteroid homolog 1 ASTE1 gene. (PMID:23344038)
• ASTE1 promotes shieldin-complex-mediated DNA repair by attenuating end resection. (PMID:34354233)
• ASTE1 frameshift mutation triggers the immune response in Epstein-Barr virus-associated gastric cancer. (PMID:34983924)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	ASTE1	ENSDARG00000062530
mus_musculus	Aste1	ENSMUSG00000032567
rattus_norvegicus	Aste1	ENSRNOG00000013059
drosophila_melanogaster	ast	FBGN0015905

Protein

Protein identifiers

Single-strand DNA endonuclease ASTE1 — Q2TB18 (reviewed: Q2TB18)

Alternative names: Protein asteroid homolog 1

All UniProt accessions (7): A0A1Y8EM16, Q2TB18, D6R9W5, D6RG30, D6RGH3, D6RJF1, H0Y982

UniProt curated annotations — full annotation on UniProt →

Function. Structure-specific DNA endonuclease that specifically cleaves single-stranded DNA and 3’ overhang DNA. Contributes to the control of DNA double-strand break repair choice by antagonizing BRCA1-dependent homologous recombination (HR) and promoting non-homologous end-joining (NHEJ). Recruited to the single-stranded DNA ends by SHLD2 and cleaves the 3’ exposed DNA ends, therefore inhibiting DNA end resection (necessary for HR) and promoting DNA end protection (necessary for NHEJ).

Subunit / interactions. Interacts with SHLD1, SHLD2, SHLD3, RIF1 and MAD2L2/REV7.

Similarity. Belongs to the asteroid family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q2TB18-1	1	yes
Q2TB18-2	2

RefSeq proteins (2): NP_001275879, NP_054784* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR006085	XPG_DNA_repair_N	Domain
IPR026832	Asteroid	Family
IPR029060	PIN-like_dom_sf	Homologous_superfamily

Pfam: PF00752

UniProt features (15 total): sequence conflict 8, region of interest 2, splice variant 2, chain 1, compositionally biased region 1, mutagenesis site 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q2TB18-F1	85.40	0.69

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Mutagenesis-validated functional residues (1):

Position	Phenotype
252	loss of single-strand dna endonuclease activity.

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 89 (showing top): GOMF_ENDONUCLEASE_ACTIVITY, BUYTAERT_PHOTODYNAMIC_THERAPY_STRESS_DN, GOMF_NUCLEASE_ACTIVITY, GOBP_DNA_DAMAGE_RESPONSE, NOUZOVA_TRETINOIN_AND_H4_ACETYLATION, GOBP_RECOMBINATIONAL_REPAIR, chr3q22, GOMF_DNA_ENDONUCLEASE_ACTIVITY, GOBP_DNA_METABOLIC_PROCESS, GOBP_DNA_REPAIR, GOMF_HYDROLASE_ACTIVITY_ACTING_ON_ESTER_BONDS, GOBP_DNA_RECOMBINATION, GARGALOVIC_RESPONSE_TO_OXIDIZED_PHOSPHOLIPIDS_GREEN_DN, GOMF_SINGLE_STRANDED_DNA_ENDODEOXYRIBONUCLEASE_ACTIVITY, GOMF_CATALYTIC_ACTIVITY_ACTING_ON_DNA

GO Biological Process (3): double-strand break repair via homologous recombination (GO:0000724), double-strand break repair via nonhomologous end joining (GO:0006303), DNA recombination (GO:0006310)

GO Molecular Function (6): single-stranded DNA endonuclease activity (GO:0000014), 3’ overhang single-stranded DNA endonuclease activity (GO:1990599), nuclease activity (GO:0004518), DNA endonuclease activity (GO:0004520), protein binding (GO:0005515), hydrolase activity (GO:0016787)

GO Cellular Component (0):

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
double-strand break repair	2
recombinational repair	1
DNA metabolic process	1
DNA endonuclease activity	1
hydrolase activity, acting on ester bonds	1
single-stranded DNA endonuclease activity	1
catalytic activity, acting on a nucleic acid	1
endonuclease activity	1
DNA nuclease activity	1
binding	1
catalytic activity	1

Protein interactions and networks

STRING

1186 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ASTE1	TAF1B	Q53T94	801
ASTE1	USF3	Q68DE3	513
ASTE1	PCNX2	A6NKB5	474
ASTE1	CASP5	P51878	448
ASTE1	POC1B	Q8TC44	447
ASTE1	TUBGCP2	Q9BSJ2	443
ASTE1	ACVR2A	P27037	436
ASTE1	LRTM3	Q8NDH2	431
ASTE1	RIF1	Q5UIP0	424
ASTE1	TGFBR2	P37173	421
ASTE1	AIM2	O14862	420
ASTE1	SLC22A9	Q8IVM8	389
ASTE1	LTN1	O94822	378
ASTE1	FAM161A	Q3B820	376
ASTE1	GAGE12J	A6NER3	371

IntAct

23 interactions, top by confidence:

A	B	Type	Score
XRCC4	ASTE1	psi-mi:“MI:0915”(physical association)	0.560
ASTE1	XRCC4	psi-mi:“MI:0915”(physical association)	0.560
ASTE1	USP47	psi-mi:“MI:0914”(association)	0.530
Dctn3		psi-mi:“MI:0914”(association)	0.350
Mis12		psi-mi:“MI:0914”(association)	0.350
CDC42	BBX	psi-mi:“MI:0914”(association)	0.350
ZWINT	ARHGAP32	psi-mi:“MI:0914”(association)	0.350
Mtx2	NRDC	psi-mi:“MI:0914”(association)	0.350
MYH11	TBC1D31	psi-mi:“MI:0914”(association)	0.350
KIF20B	ACSL3	psi-mi:“MI:0914”(association)	0.350
GAR1	TAF1	psi-mi:“MI:0914”(association)	0.350
TMEM248	TAF1	psi-mi:“MI:0914”(association)	0.350
Tgs1	EFCAB5	psi-mi:“MI:0914”(association)	0.350
NABP1	XPO1	psi-mi:“MI:0914”(association)	0.350
CDK2	MRPL27	psi-mi:“MI:0914”(association)	0.350
GOLT1B		psi-mi:“MI:0914”(association)	0.350
ZNF692	NSD2	psi-mi:“MI:0914”(association)	0.350
CCDC85A	CIBAR1	psi-mi:“MI:0914”(association)	0.350
ASTE1	yopM	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (23): ASTE1 (Two-hybrid), ASTE1 (Affinity Capture-MS), ASTE1 (Affinity Capture-MS), ASTE1 (Affinity Capture-MS), ASTE1 (Affinity Capture-MS), ASTE1 (Affinity Capture-MS), ASTE1 (Affinity Capture-MS), ASTE1 (Affinity Capture-MS), ASTE1 (Affinity Capture-MS), ASTE1 (Affinity Capture-MS), ASTE1 (Affinity Capture-MS), ASTE1 (Affinity Capture-MS), ASTE1 (Affinity Capture-MS), ASTE1 (Affinity Capture-MS), USP47 (Affinity Capture-MS)

ESM2 similar proteins: A0A571BF63, A2BF66, A6QQY4, B0BN28, D3ZWE7, E2QXH7, F6RRD7, O02799, O60566, O70481, O95905, P52630, Q05B18, Q0V7M7, Q13257, Q28IH8, Q2KIY6, Q2TB18, Q3B7T8, Q3U1T9, Q3UB74, Q4R8B9, Q5JTW2, Q5M7C8, Q5PQQ9, Q5RA37, Q5RCY5, Q5SQP1, Q5XGL1, Q5XIZ9, Q6IQY5, Q7T0S7, Q86VD1, Q86VS3, Q86X24, Q8C5W4, Q8CDK3, Q8IWV7, Q8IXW5, Q8N7B1

Diamond homologs: Q1LYL8, Q2TB18, Q5RCY5, Q8BIR2

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

111 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	96
Likely benign	8
Benign	1

Top pathogenic / likely-pathogenic (0)

SpliceAI

1372 predictions. Top by Δscore:

Variant	Effect	Δscore
3:131014384:CAGT:C	acceptor_gain	1.0000
3:131014388:C:CC	acceptor_gain	1.0000
3:131016138:GCTTA:G	donor_loss	1.0000
3:131016142:A:AC	donor_gain	1.0000
3:131016142:ACCGA:A	donor_loss	1.0000
3:131016143:C:CC	donor_gain	1.0000
3:131019644:T:TA	donor_gain	1.0000
3:131014386:GT:G	acceptor_gain	0.9900
3:131014387:TC:T	acceptor_loss	0.9900
3:131014388:C:G	acceptor_loss	0.9900
3:131014393:C:CT	acceptor_gain	0.9900
3:131016335:CTTAC:C	acceptor_gain	0.9900
3:131016337:TAC:T	acceptor_gain	0.9900
3:131016340:CTAA:C	acceptor_loss	0.9900
3:131016989:CCTT:C	donor_gain	0.9900
3:131018500:ACCT:A	donor_loss	0.9900
3:131018501:CCT:C	donor_loss	0.9900
3:131018502:CTACC:C	donor_loss	0.9900
3:131018503:TAC:T	donor_loss	0.9900
3:131018504:A:AC	donor_gain	0.9900
3:131018504:ACCAG:A	donor_loss	0.9900
3:131018505:C:CC	donor_gain	0.9900
3:131018505:CCAG:C	donor_loss	0.9900
3:131018575:G:C	donor_gain	0.9900
3:131024001:TTACC:T	donor_loss	0.9900
3:131024002:TA:T	donor_loss	0.9900
3:131024004:CCT:C	donor_gain	0.9900
3:131024650:C:CT	acceptor_gain	0.9900
3:131026505:A:AC	donor_gain	0.9900
3:131026506:C:CC	donor_gain	0.9900

AlphaMissense

4461 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
3:131016220:A:G	W545R	0.995
3:131016220:A:T	W545R	0.995
3:131025303:C:G	G2R	0.994
3:131025080:A:T	V76D	0.992
3:131024651:G:T	A219E	0.990
3:131024824:A:C	S161R	0.989
3:131024824:A:T	S161R	0.989
3:131024826:T:G	S161R	0.989
3:131024188:C:A	R373S	0.988
3:131024188:C:G	R373S	0.988
3:131024861:G:T	A149D	0.988
3:131024821:G:C	D162E	0.986
3:131024821:G:T	D162E	0.986
3:131024822:T:A	D162V	0.986
3:131024822:T:C	D162G	0.986
3:131024840:A:T	V156E	0.986
3:131025022:T:A	R95S	0.986
3:131025022:T:G	R95S	0.986
3:131024822:T:G	D162A	0.985
3:131025303:C:A	G2C	0.985
3:131016189:A:G	L555P	0.984
3:131024086:C:A	R407S	0.984
3:131024086:C:G	R407S	0.984
3:131024769:A:G	W180R	0.984
3:131024769:A:T	W180R	0.984
3:131024827:A:C	D160E	0.984
3:131024827:A:T	D160E	0.984
3:131025000:C:G	A103P	0.984
3:131025068:C:T	G80E	0.984
3:131024189:C:G	R373T	0.983

dbSNP variants (sampled 300 via entrez): RS1000438403 (3:131018166 G>C), RS1000612831 (3:131017599 G>GAGGTATTA), RS1000684954 (3:131017924 T>A), RS1000723679 (3:131016876 T>C), RS1000776319 (3:131016580 G>A,C,T), RS1000889552 (3:131023256 C>T), RS1000895890 (3:131017346 G>T), RS1000896107 (3:131023780 G>A), RS1001395728 (3:131019842 C>T), RS1001555640 (3:131026482 C>T), RS1002048758 (3:131026212 T>C), RS1002183186 (3:131018003 ATTACTATT>A), RS1002416243 (3:131024270 A>C), RS1002514662 (3:131027518 G>A), RS1002685923 (3:131014062 C>G,T)

Disease associations

OMIM: gene MIM:620693 | disease phenotypes:

GenCC curated gene-disease

Disease	Classification	Inheritance
palmar fibromatosis	Limited	Autosomal dominant

Mondo (1): palmar fibromatosis (MONDO:0006345)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

2 associations (top):

Study	Trait	p-value
GCST005042_7	Restless legs syndrome	4.000000e-38
GCST008755_11	Phenylephrine infusion rate during anesthesia	9.000000e-06

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D004387	Dupuytren Contracture	C04.557.450.565.590.340.173; C05.651.197.270; C17.300.270

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

20 total (human), top 20 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
3-((6-(2-methoxyphenyl)pyrimidin-4-yl)amino)phenyl)methane sulfonamide	decreases expression	1
GSK-J4	decreases expression	1
dicrotophos	decreases expression	1
urushiol	decreases expression	1
triphenyl phosphate	affects expression	1
butyraldehyde	decreases expression	1
di-n-butylphosphoric acid	affects expression	1
CGP 52608	affects binding, increases reaction	1
CPG-oligonucleotide	decreases expression	1
Resveratrol	increases expression, affects cotreatment	1
Acetaminophen	increases expression	1
Air Pollutants, Occupational	affects expression	1
Methyl Methanesulfonate	increases expression	1
Plant Extracts	affects cotreatment, increases expression	1
Quercetin	decreases expression	1
Testosterone	decreases expression	1
Tretinoin	decreases expression	1
Cyclosporine	decreases expression	1
Aflatoxin B1	decreases methylation	1
Copper Sulfate	decreases expression	1

Cellosaurus cell lines

2 cell lines: 2 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_E1R3	HAP1 ASTE1 (-) 1	Cancer cell line	Male
CVCL_E1R4	HAP1 ASTE1 (-) 2	Cancer cell line	Male

Clinical trials (associated diseases)

29 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT02647619	PHASE4	COMPLETED	Dupuytren´s Disease Study. Primary Disease, MCP Joint, Xiapex, PNF
NCT03000114	PHASE4	UNKNOWN	Collagenase Injection vs Percutaneous Needle Aponeurotomy for Dupuytren’s Disease
NCT03192020	PHASE4	ACTIVE_NOT_RECRUITING	Trial Comparing Treatment Strategies in Dupuytren’s Contracture
NCT04907812	PHASE4	UNKNOWN	The Role of Tranexamic Acid in Reducing Post Operative Hand Edema After Hand and Wrist Surgery
NCT05440240	PHASE4	RECRUITING	Percutaneous Needle Fasciotomy +/- Corticosteroid Injection for Dupuytren’s Contracture
NCT06806410	PHASE4	ACTIVE_NOT_RECRUITING	The Efficacy of Liposomal Bupivacaine in Ultrasound Guided Supraclavicular Nerve Blocks for Hand and Wrist Surgery
NCT01776892	PHASE3	WITHDRAWN	Collagenase and Needle Aponeurotomy: Single Modality Versus Combination Treatment for Dupuytren’s Disease
NCT04874870	PHASE3	COMPLETED	Effectiveness of Splinting After Collagenase Injection
NCT01184586	PHASE2	UNKNOWN	Dupuytren’s Disease and Extracorporeal Shockwave Therapy (DupuyShock-2010)
NCT03111186	PHASE2	COMPLETED	Ibuprofen Plus Acetaminophen Versus Oxycodone Alone After Hand Surgery
NCT07227649	PHASE2	NOT_YET_RECRUITING	NAC-REPAIR for Post-surgical Pain
NCT01876498	Not specified	COMPLETED	Registry of Patient With M. Dupuytren and Validation of the Brief MHQ
NCT01923103	Not specified	COMPLETED	Natural Disease Progress of Dupuytren Disease
NCT02983162	Not specified	COMPLETED	Is wGRS Associated With DD Recurrence?
NCT03031080	Not specified	WITHDRAWN	BOND Study: the Benefit Of Night Splinting in Dupuytrens'
NCT03155854	Not specified	RECRUITING	The Effects of Prophylactic Limited Palmar Fasciectomy on Surgical Outcomes and Scarring
NCT03331926	Not specified	COMPLETED	Collagenase is a Common Treatment of MCP and PIP Joint Contractures in Dupuytrens Disease
NCT03407820	Not specified	COMPLETED	Nylon Versus Chromic Gut Sutures for Minor Hand Surgery
NCT03573765	Not specified	COMPLETED	Epidemiology and Outcomes of Upper Limb Surgery: Analysis of Routine Data
NCT03741764	Not specified	UNKNOWN	Treatment of Dupuytren’s Disease With Minimal Invasive Surgery and VIVOSORB® Resorbable Implant Device
NCT03868449	Not specified	COMPLETED	Question Prompt List for Common Hand Conditions
NCT03982719	Not specified	UNKNOWN	Comparing the Effectiveness of Two Post-fasciectomy Rehabilitation Protocols in Patients With Dupuytren’s Disease
NCT04122313	Not specified	RECRUITING	Post-contracture Release Radiation for Dupuytren’s Disease
NCT05300893	Not specified	RECRUITING	Effectiveness of Night Splinting After Percutaneous Needle Fasciotomy in Dupuytren’s Contracture
NCT06248866	Not specified	UNKNOWN	Effect Of Extracorporeal Shock Wave Therapy On Ultrasonography Changes In Patients With Palmar Fibromatosis: A Randomized Controlled Trial
NCT06330545	Not specified	RECRUITING	Radiation Therapy for Dupuytren’s Contracture Following Non-Surgical Release
NCT06788847	Not specified	RECRUITING	Evaluating Ultrasound-Guided Needle Knife for Dupuytren’s Contracture
NCT07158892	Not specified	NOT_YET_RECRUITING	Understanding Patient Preferences When Deciding on a Voluntary Musculoskeletal Test
NCT07443371	Not specified	NOT_YET_RECRUITING	Effect of Transfer Energy Capacitive and Resistive Therapy on Palmar Fibromatosis